CN110087666B - 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法 - Google Patents

用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法 Download PDF

Info

Publication number
CN110087666B
CN110087666B CN201780069543.0A CN201780069543A CN110087666B CN 110087666 B CN110087666 B CN 110087666B CN 201780069543 A CN201780069543 A CN 201780069543A CN 110087666 B CN110087666 B CN 110087666B
Authority
CN
China
Prior art keywords
img
seq
gly
levels
rps2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780069543.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110087666A (zh
Inventor
恩戈克·泰
乔纳森·波莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imagine Pharma LLC
Original Assignee
Imagine Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma LLC filed Critical Imagine Pharma LLC
Publication of CN110087666A publication Critical patent/CN110087666A/zh
Application granted granted Critical
Publication of CN110087666B publication Critical patent/CN110087666B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780069543.0A 2016-11-13 2017-11-13 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法 Active CN110087666B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421332P 2016-11-13 2016-11-13
US62/421,332 2016-11-13
PCT/US2017/061343 WO2018089909A1 (en) 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Publications (2)

Publication Number Publication Date
CN110087666A CN110087666A (zh) 2019-08-02
CN110087666B true CN110087666B (zh) 2024-04-30

Family

ID=62107069

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780069543.0A Active CN110087666B (zh) 2016-11-13 2017-11-13 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法

Country Status (9)

Country Link
US (2) US10548941B2 (enExample)
EP (1) EP3538124A4 (enExample)
JP (3) JP2020502056A (enExample)
KR (1) KR102497242B1 (enExample)
CN (1) CN110087666B (enExample)
AU (2) AU2017357052B2 (enExample)
BR (1) BR112019009511A2 (enExample)
MX (1) MX2019005466A (enExample)
WO (1) WO2018089909A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087666B (zh) * 2016-11-13 2024-04-30 想象制药公司 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
JP2021510157A (ja) * 2018-01-09 2021-04-15 イマジン ファーマ、エルエルシー 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用
WO2020005721A1 (en) * 2018-06-25 2020-01-02 Imagine Pharma, Llc Compositions and methods for propagating insulin-producing islet cells and therapeutic uses thereof
CN110974943A (zh) * 2019-12-09 2020-04-10 广东药科大学 一种口服胰岛素药物制剂及其制备方法
JP2023552515A (ja) * 2020-12-08 2023-12-18 イマジン ファーマ、エルエルシー 創傷を治療するための組成物および方法
WO2023049079A2 (en) * 2021-09-22 2023-03-30 Imagine Pharma Llc Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
CA3235948A1 (en) * 2021-12-11 2023-06-15 Ngoc THAI Compositions and methods for oral administration
WO2025207834A1 (en) * 2024-03-28 2025-10-02 Imagine Pharma Llc Dietary supplements, compositions, and uses thereof for increasing telomerase activity and extending telomere length

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064625A1 (en) * 2001-02-15 2002-08-22 Chondrogenesis Pty Ltd. Matrix gene expression in chondrogenesis
WO2003068908A2 (en) * 2001-07-10 2003-08-21 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
WO2005000335A2 (en) * 2003-06-02 2005-01-06 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2008127813A1 (en) * 2007-03-09 2008-10-23 Hiberna Corporation Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use
CA3041362A1 (en) * 2016-11-13 2018-05-17 Imagine Pharma, Llc Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
CN112423772A (zh) * 2018-01-09 2021-02-26 想象制药有限责任公司 Rps2肽调节内皮细胞功能障碍的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4025395B2 (ja) * 1997-04-09 2007-12-19 花王株式会社 新規ペクチン酸リアーゼ
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
EP2275120A3 (en) * 2002-04-02 2011-06-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
JP2005245202A (ja) * 2004-03-01 2005-09-15 Japan Science & Technology Agency ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能
US9221886B2 (en) * 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2012054739A2 (en) * 2010-10-21 2012-04-26 New York University Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
CA2817851A1 (en) * 2010-11-12 2012-05-18 The Johns Hopkins University Albumin-bound protein/peptide complex as a biomarker for disease
ES3039965T3 (en) 2011-03-01 2025-10-28 NuCana plc Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
EP3048904A2 (en) * 2013-09-25 2016-08-03 Pronutria Biosciences, Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
MD20170035A2 (ro) * 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
WO2017109706A1 (en) * 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064625A1 (en) * 2001-02-15 2002-08-22 Chondrogenesis Pty Ltd. Matrix gene expression in chondrogenesis
WO2003068908A2 (en) * 2001-07-10 2003-08-21 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
WO2005000335A2 (en) * 2003-06-02 2005-01-06 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2008127813A1 (en) * 2007-03-09 2008-10-23 Hiberna Corporation Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use
CA3041362A1 (en) * 2016-11-13 2018-05-17 Imagine Pharma, Llc Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
CN112423772A (zh) * 2018-01-09 2021-02-26 想象制药有限责任公司 Rps2肽调节内皮细胞功能障碍的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Comprehensive analysis and validation of novel immune and vascular remodeling related genes signature associated with drug interactions in pulmonary arterial hypertension;Jie Wang等;《Frontiers in Genetics》;20220906;全文 *
Identification of Key Pathways and Genes in Obesity Using Bioinformatics Analysis and Molecular Dock Studies;Joshi Harish等;《Frontiers in Endocrinology》;20210624;全文 *

Also Published As

Publication number Publication date
CN110087666A (zh) 2019-08-02
JP2023071670A (ja) 2023-05-23
EP3538124A4 (en) 2020-07-22
AU2017357052B2 (en) 2022-03-24
EP3538124A1 (en) 2019-09-18
JP2020502056A (ja) 2020-01-23
US20180133280A1 (en) 2018-05-17
AU2017357052A1 (en) 2019-05-02
KR20190084070A (ko) 2019-07-15
JP2025163025A (ja) 2025-10-28
KR102497242B1 (ko) 2023-02-09
JP7711967B2 (ja) 2025-07-23
AU2022203741A1 (en) 2022-06-23
US10548941B2 (en) 2020-02-04
US20200222499A1 (en) 2020-07-16
CA3041362A1 (en) 2018-05-17
AU2022203741B2 (en) 2024-02-15
BR112019009511A2 (pt) 2019-07-30
WO2018089909A1 (en) 2018-05-17
MX2019005466A (es) 2019-10-02
US10751384B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
CN110087666B (zh) 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
ES2307619T3 (es) Tratamiento del sindrome coronario agudo con glp-1.
US20200353054A1 (en) Use of ave0010 for the treatment of diabetes mellitus type 2
US20140329742A1 (en) Therapeutic peptides
JPH0196137A (ja) 真性糖尿病の治療
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
EP3268029B1 (en) Treatment of type 2 diabetes mellitus patients
WO2019201328A1 (zh) 酰化的glp-1衍生物
US11236142B2 (en) Acylated oxyntomodulin peptide analog
CN112279920A (zh) FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
US20080194483A1 (en) GLP-1 (9-36) methods and compositions
KR20210013543A (ko) 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도
US11612637B2 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US20230263856A1 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
CA3041362C (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
JP2016526533A (ja) アミリンミメティック化合物とポリエチレングリコールの非凝集バイオ接合体
CN111744006A (zh) 一种用于防治糖尿病视网膜病变的药物组合物
HK1244216B (en) Treatment of type 2 diabetes mellitus patients
HK1185807B (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
HK1185807A (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
WO2010121351A1 (en) Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant